Rebalix
Logo VanguardVanguard · sheet of 5 September 2026
ETF sheet · official issuer and register data

Vanguard FTSE Developed Europe ex UK UCITS ETF (EUR) Accumulating

VERE · IE00BK5BQY34 · EUR · domicile Ireland
Equity · EuropeSFDR art. 6 (inferred)
Index tracked: FTSE Developed Europe ex UK Index
TER
0.10%+ trans. 0.04%
Fund size
4.8 bn EUR
Tracking difference
+0.47%3-year avg
🇮🇹 tax rate
26.00%equity
Replication
Physical (sampled)
Income
Accumulating
Launch 23 Jul 2019 · costs from the KID as of 2 Sept 2026 · 446 securities held · 9 venues (ESMA register)

The fund’s objective — in the issuer’s words

From the Key Information Document (KID) · 4 Aug 2026
The Fund employs a passive management – or indexing – investment approach, through physical acquisition of securities, and seeks to track the performance of the FTSE Developed Europe ex U.K. Index (the “Index”). The Index is comprised of large and mid-sized company stocks in developed markets in Europe, excluding the UK. The Fund attempts to: 1. Track the performance of the Index by investing through physical acquisition in all constituent securities of the Index in the same proportion as the Index. Where not practicable to fully replicate, the Fund will…

Performance since series start (in euro) — base 100

31 Aug 201931 Jul 2026 · dividends reinvested where declared by the issuer
202020212022202320242025202620786207
High 207 (31 Jul 2026) · low 86 (31 Mar 2020) · last 207. Past performance is not indicative of future results.

Returns in euro

1 year+22.3%
3 years+48.3%
5 years+61.1%
10 yearsseries too young
Since series start+107.4%

Risk · 1 / 3 / 5 years

Volatility (ann.)12.97%12.88%14.60%
Max drawdown−10.09%−16.10%−22.97%
Sharpe1.390.890.48
Sortino2.161.260.68
Sharpe/Sortino: risk-free = ECB MRO avg; nominal volatility
Rebalix · VERE · IE00BK5BQY341
RebalixVERE · IE00BK5BQY34 · sheet of 5 September 2026

Tracking difference — year by year

Fund minus index, complete calendar years · from issuer-declared series
YearFundIndexTD
2025+20.67%+20.16%+0.51%
2024+7.33%+6.88%+0.45%
2023+18.13%+17.67%+0.46%
2022−12.74%−13.13%+0.39%
2021+24.92%+24.46%+0.45%

Holdings

Portfolio as declared by the issuer · 31 Jul 2026 · 446 securities · top-10 weight = 23.4%
Top holdingsWeight
ASML Holding NV5.6%
Roche Holding AG2.7%
Novartis AG2.6%
Nestle SA2.3%
Siemens AG2.1%
Banco Santander SA1.8%
Allianz SE1.7%
SAP SE1.6%
Schneider Electric SE1.6%
TotalEnergies SE1.5%
Countries (% of fund)
France19.1%Switzerland18.8%Germany17.4%Netherlands10.6%Spain8.1%
Sectors (% of fund)
Financials25.5%Industrials20.2%Health Care12.9%Technology10.5%Consumer Discretionary8.2%

Listing venues

ESMA register (FIRDS) and official exchange lists
VERE · Borsa Italiana (ETFplus), Börse Düsseldorf, Börse Frankfurt, Börse Hamburg, Börse Hannover, Börse München / gettex, Börse Stuttgart, Tradegate Exchange, Xetra (Deutsche Börse)
+ 19 unmapped venues (MTF, RFQ, professional)

Official documents

Clickable links in the PDF
KID · fund-docs.vanguard.com/ie00bk5bqy34_priipskid_en.pdf
Factsheet · fund-docs.vanguard.com/FTSE_Developed_Europe_ex_UK_UCITS_ETF_EUR_Accum
Prospectus · fund-docs.vanguard.com/etf-prospectus-en.pdf
The live sheet, always up to date
rebalix.com/en/etf/IE00BK5BQY34
Series, distributions, holdings and documents refresh daily.
Sheet produced on 5 September 2026 · data as of the dates shown section by section. Sources: official issuer documents (KID, factsheet, NAV and total-return series, declared portfolio), ESMA register (FIRDS), European Central Bank (FX), Italian tax authority / issuer (white-list share). Public methodology: rebalix.com/en/methodology. “—” = not published by the source, never estimated.

Informational document generated by rebalix.com: facts only, no recommendations. Not investment advice or investment research under Directive 2014/65/EU (MiFID II), nor an offer or solicitation. Past performance is not indicative of, nor a guarantee of, future results; the value of an investment can go down as well as up. Before any decision read the issuer’s KID and Prospectus; tax treatment depends on individual circumstances. Trademarks and logos belong to their respective owners and only identify the instrument and its issuer: no affiliation, sponsorship or endorsement.

Rebalix · VERE · IE00BK5BQY342